231 related articles for article (PubMed ID: 27755105)
1. Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir.
Darcis G; Bouchat S; Kula A; Van Driessche B; Delacourt N; Vanhulle C; Avettand-Fenoel V; De Wit S; Rohr O; Rouzioux C; Van Lint C
AIDS; 2017 Jan; 31(2):181-189. PubMed ID: 27755105
[TBL] [Abstract][Full Text] [Related]
2. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
[TBL] [Abstract][Full Text] [Related]
3. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments.
Kula A; Delacourt N; Bouchat S; Darcis G; Avettand-Fenoel V; Verdikt R; Corazza F; Necsoi C; Vanhulle C; Bendoumou M; Burny A; De Wit S; Rouzioux C; Rohr O; Van Lint C
J Acquir Immune Defic Syndr; 2019 Apr; 80(5):605-613. PubMed ID: 30768485
[TBL] [Abstract][Full Text] [Related]
5. Curaxin CBL0137 has the potential to reverse HIV-1 latency.
Jean MJ; Zhou D; Fiches G; Kong W; Huang H; Purmal A; Gurova K; Santoso NG; Zhu J
J Med Virol; 2019 Aug; 91(8):1571-1576. PubMed ID: 30989696
[TBL] [Abstract][Full Text] [Related]
6. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
[TBL] [Abstract][Full Text] [Related]
7. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
J Virol; 2017 May; 91(9):. PubMed ID: 28202759
[TBL] [Abstract][Full Text] [Related]
8. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
9. Limited HIV-1 Reactivation in Resting CD4
Kumar A; Abbas W; Bouchat S; Gatot JS; Pasquereau S; Kabeya K; Clumeck N; De Wit S; Van Lint C; Herbein G
Sci Rep; 2016 Dec; 6():38313. PubMed ID: 27922055
[TBL] [Abstract][Full Text] [Related]
10. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
Grau-Expósito J; Luque-Ballesteros L; Navarro J; Curran A; Burgos J; Ribera E; Torrella A; Planas B; Badía R; Martin-Castillo M; Fernández-Sojo J; Genescà M; Falcó V; Buzon MJ
PLoS Pathog; 2019 Aug; 15(8):e1007991. PubMed ID: 31425551
[TBL] [Abstract][Full Text] [Related]
11. Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients.
Bouchat S; Gatot JS; Kabeya K; Cardona C; Colin L; Herbein G; De Wit S; Clumeck N; Lambotte O; Rouzioux C; Rohr O; Van Lint C
AIDS; 2012 Jul; 26(12):1473-82. PubMed ID: 22555163
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
Banga R; Procopio FA; Cavassini M; Perreau M
J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
[TBL] [Abstract][Full Text] [Related]
13. T cell toxicity of HIV latency reversing agents.
Zhao M; De Crignis E; Rokx C; Verbon A; van Gelder T; Mahmoudi T; Katsikis PD; Mueller YM
Pharmacol Res; 2019 Jan; 139():524-534. PubMed ID: 30366100
[TBL] [Abstract][Full Text] [Related]
14. Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4
Kulpa DA; Talla A; Brehm JH; Ribeiro SP; Yuan S; Bebin-Blackwell AG; Miller M; Barnard R; Deeks SG; Hazuda D; Chomont N; Sékaly RP
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578289
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation.
Noel N; Peña R; David A; Avettand-Fenoel V; Erkizia I; Jimenez E; Lecuroux C; Rouzioux C; Boufassa F; Pancino G; Venet A; Van Lint C; Martinez-Picado J; Lambotte O; Sáez-Cirión A; Prado JG
J Virol; 2016 Jul; 90(13):6148-6158. PubMed ID: 27122576
[TBL] [Abstract][Full Text] [Related]
16. Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.
Gupta V; Dixit NM
PLoS Comput Biol; 2018 Feb; 14(2):e1006004. PubMed ID: 29451894
[TBL] [Abstract][Full Text] [Related]
17. Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells.
López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Vivancos MJ; Luna L; Moreno S
Biochem Pharmacol; 2020 Dec; 182():114231. PubMed ID: 32979351
[TBL] [Abstract][Full Text] [Related]
18. RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency.
Méndez C; Ledger S; Petoumenos K; Ahlenstiel C; Kelleher AD
Retrovirology; 2018 Oct; 15(1):67. PubMed ID: 30286764
[TBL] [Abstract][Full Text] [Related]
19. A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.
Jones RB; Mueller S; O'Connor R; Rimpel K; Sloan DD; Karel D; Wong HC; Jeng EK; Thomas AS; Whitney JB; Lim SY; Kovacs C; Benko E; Karandish S; Huang SH; Buzon MJ; Lichterfeld M; Irrinki A; Murry JP; Tsai A; Yu H; Geleziunas R; Trocha A; Ostrowski MA; Irvine DJ; Walker BD
PLoS Pathog; 2016 Apr; 12(4):e1005545. PubMed ID: 27082643
[TBL] [Abstract][Full Text] [Related]
20. The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.
Clutton G; Xu Y; Baldoni PL; Mollan KR; Kirchherr J; Newhard W; Cox K; Kuruc JD; Kashuba A; Barnard R; Archin N; Gay CL; Hudgens MG; Margolis DM; Goonetilleke N
Sci Rep; 2016 Aug; 6():30749. PubMed ID: 27480951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
